Colorectal

Pennsylvania Law Mandates No-Cost Coverage for Colorectal Cancer Blood Tests

A new Pennsylvania law will require state-regulated insurers and Medicaid to cover blood-based colorectal cancer screening tests with no cost-sharing, Dec 21, 2026.

Abbott Blood Test Improves Detection of Residual Colorectal Cancer After Surgery
Blood-Based Colorectal Cancer Screening Averts More Deaths Than Stool Tests, Modeling Shows
Haystack MRD Accurately Predicts Colorectal Cancer Recurrence, Study Finds
Abbott Launches SimpleScreen CRC Blood Test for Colorectal Cancer Screening
CMS Expands Medicare Coverage for Colorectal Cancer Screenings to Include PA- and APRN-Ordered Tests
Carelon Adds Coverage for Guardant Health’s Shield Colorectal Cancer Blood Test
Study Finds Health System Outreach Boosts Repeat Colon Cancer Screening
Freenome Reports Clinical Validation Results for Updated Colorectal Cancer Blood Test
Blood Test May Identify Colorectal Cancer Patients Who Benefit from Chemotherapy

Colorectal

UnitedHealth Group Covers Shield Blood Test for Colorectal Cancer Screening

The Shield test is now available to eligible members aged 45 and older, expanding access to screening options for colorectal cancer.

Colorectal

Creatv Bio’s Liquid Biopsy Test Supports CytoDyn Phase 2 Colorectal Cancer Study

LifeTracDx blood test will evaluate PD-L1 expression changes as exploratory biomarker in trial combining leronlimab with standard therapies.

Walgreens Partners to Expand Colorectal Cancer Screening Access

Mar 13, 2026 | Colorectal

The initiative gives eligible pharmacy customers a streamlined pathway to request the Cologuard stool DNA test, with no prep or special diet required.

Guardant’s Shield CRC Blood Test Now Orderable Through Quest Diagnostics Network

Mar 11, 2026 | Colorectal

Physicians can now order the Shield blood test through Quest’s network of nearly 650,000 clinician and hospital accounts, patient service centers, and in-office phlebotomists.

Study Shows Dual Epigenetic Markers Improve Early Colorectal Cancer Detection

Mar 9, 2026 | Colorectal

A study reports that dual epigenetic markers in cell-free DNA achieved 95% diagnostic accuracy for stage I colorectal cancer, outperforming conventional liquid biopsy methods.

Fecal DNA Methylation Test Shows Promise for Colorectal Cancer Screening

Feb 27, 2026 | Colorectal

A multicenter study reports that combining fecal SDC2 methylation testing with the APCS scoring system improves advanced adenoma detection and specificity in colorectal cancer screening.

Guardant Health Offers Free Colorectal Cancer Screening Tests Through Community Grant Program

Feb 18, 2026 | Colorectal

Guardant Health will provide up to 100 free Shield blood tests per organization to support colorectal cancer screening events and outreach during Colorectal Cancer Awareness Month in March.

FDA Approves Companion Diagnostic for Colorectal Cancer Treatment

Jan 23, 2026 | Colorectal

The FDA has approved a companion diagnostic for identifying BRAF V600E-mutant metastatic colorectal cancer patients eligible for encorafenib combination therapy.

SAGA Diagnostics Launches Pathlight MRD Test for Colorectal Cancer Patients

Jan 12, 2026 | Colorectal

CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.

Daisy Genomics, New Day Diagnostics Partner on Colorectal Cancer Detection Platform

Jan 9, 2026 | Colorectal

The collaboration will combine New Day’s liquid biopsy technology with Daisy Genomics’ physics-based sequencing platform to advance early CRC screening.

Human Longevity Expands $1M Cancer Pledge to Include Colon Cancer

Dec 31, 2025 | Colorectal

The biotechnology company’s integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.

Blood Test Shows Promise for Tailoring Colon Cancer Chemotherapy

Oct 30, 2025 | Colorectal

Circulating tumor DNA testing can identify stage 3 patients who may safely receive reduced treatment intensity, international study finds.

Quest Diagnostics to Expand Blood-Based Colorectal Cancer Screening Access

Sep 26, 2025 | Colorectal

The company is collaborating with Guardant Health to make Guardant’s Shield test available through Quest’s nationwide network of provider clients and patient service centers.